2026-06-28T14:58:47Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1293012025-12-19T01:23:52Zcom_20.500.14352_14col_20.500.14352_15

00925njm 22002777a 4500 dc Lago Rodríguez, Marta Olimpia author López Rubio, Mariana author Moragón Ledesma, Sergio author Oblitas, Crhistian Mario author Galeano Valle, Francisco author Atienza Fernández, Felipe author Carta, Alejandro author Demelo Rodríguez, Pablo author 2024-10-01 Pacemakers (PM) and implantable cardioverter-defibrillators are vital devices in contemporary clinical practice, but their growing adoption poses challenges. Complications, including lead migration, infections, and post-implantation venous thrombosis, underscore the importance of comprehensive investigation. This retrospective observational study enrolled patients diagnosed with upper limb deep vein thrombosis (DVT) secondary to intracardiac devices at a tertiary hospital from 2015 to 2022. The aim of the study was to determine the incidence and long-term outcomes (bleeding, DVT recurrence and sequelae) in these patients. Across the study period, 2681 intracardiac devices were implanted, with 12 cases of upper limb DVT documented. The majority of patients were male (91.7%), with a mean age of 63.92 years. DVT occurred in patients with PM (50%), implantable cardioverter-defibrillators (25%) and implantable cardioverter-defibrillators with Cardiac Resynchronization Therapy (25%). Treatment encompassed low-molecular-weight heparin (91.7%) during the acute episode and long-term anticoagulation with direct oral anticoagulants (75%) or vitamin K antagonists (25%). Over a mean follow-up period of 33.17 months, half of the patients exhibited long-term sequelae, notably collateral circulation (66.7%). Remarkably, no thrombosis recurrences were observed during follow-up. However, one patient (8.3%) experienced a major bleeding event during treatment, and one patient (8.3%) required device removal (PM) due to persistent symptoms. This study revealed upper limb DVT occurred in 0.45% of patients after intracardiac device implantation. Rate of thrombosis recurrence was low during follow-up. Although half of the patients developed long-term sequelae, the need for prolonged anticoagulant therapy in these cases remains uncertain. Lago-Rodríguez MO, López-Rubio M, Moragón-Ledesma S, Oblitas CM, Galeano-Valle F, Atienza F, Carta A, Demelo-Rodríguez P. Incidence and long-term outcomes of upper limb deep vein thrombosis associated with intracardiac devices: analysis of bleeding, recurrence, and sequelae. Intern Emerg Med. 2024;19(7):1959-1966. doi: 10.1007/s11739-024-03710-8. Epub 2024 Aug 8. PMID: 39112732. 1828-0447 10.1007/s11739-024-03710-8 https://hdl.handle.net/20.500.14352/129301 1970-9366 https://doi.org/10.1007/s11739-024-03710-8 39112732 https://link.springer.com/article/10.1007/s11739-024-03710-8 https://pubmed.ncbi.nlm.nih.gov/39112732/ Incidence and long-term outcomes of upper limb deep vein thrombosis associated with intracardiac devices: analysis of bleeding, recurrence, and sequelae